Market Access

How medicines move from regulatory approval to patient availability. Covers pricing, reimbursement, HTA processes, and the strategic decisions that determine whether a drug actually reaches the people it was developed for.

Tools & Productivity

Five free resources every health economist should bookmark

Jun 2, 2026

•

5 min read

Five free resources every health economist should bookmark

The tools I reach for most, what justifies each one, and the "gotcha" to watch out for.

Mirko von Hein

Behind-the-scenes

May 11, 2026

•

2 min read

I've quit pharma. Am I mad?

Why I left Gilead, what Von Hein Consulting does, and what doesn't change for this newsletter.

Mirko von Hein

Tools & Productivity

You're Doing Expert Elicitation Wrong (And So Was I)

Mar 23, 2026

•

3 min read

You're Doing Expert Elicitation Wrong (And So Was I)

What defensible expert elicitation actually looks like — and a tool that makes it possible

Mirko von Hein

Market Access

The UK's Innovation Dilemma: Is Britain Pricing Itself Out of the Medicine Market?

Feb 16, 2026

•

6 min read

The UK's Innovation Dilemma: Is Britain Pricing Itself Out of the Medicine Market?

The UK spends significantly less of its health budget on branded medicines than comparable nations. Termination rates in the appraisal process have doubled. And companies are increasingly choosing not to launch here at all. A conversation with the ABPI's Jack Neill-Hall about what's at stake—and where the opportunity lies.

Mirko von Hein

Market Access

Five free resources every health economist should bookmark

I've quit pharma. Am I mad?

You're Doing Expert Elicitation Wrong (And So Was I)

The UK's Innovation Dilemma: Is Britain Pricing Itself Out of the Medicine Market?

The HEOR Intel You Actually Need

Tracking what matters in HEOR, market access, and pharma consulting for your career success